Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 186
1.
J Neuroinflammation ; 21(1): 135, 2024 May 27.
Article En | MEDLINE | ID: mdl-38802931

Traumatic brain injury (TBI) is a major cause of disability and mortality worldwide, particularly among the elderly, yet our mechanistic understanding of what renders the post-traumatic brain vulnerable to poor outcomes, and susceptible to neurological disease, is incomplete. It is well established that dysregulated and sustained immune responses elicit negative consequences after TBI; however, our understanding of the neuroimmune interface that facilitates crosstalk between central and peripheral immune reservoirs is in its infancy. The meninges serve as the interface between the brain and the immune system, facilitating important bi-directional roles in both healthy and disease settings. It has been previously shown that disruption of this system exacerbates neuroinflammation in age-related neurodegenerative disorders such as Alzheimer's disease; however, we have an incomplete understanding of how the meningeal compartment influences immune responses after TBI. In this manuscript, we will offer a detailed overview of the holistic nature of neuroinflammatory responses in TBI, including hallmark features observed across clinical and animal models. We will highlight the structure and function of the meningeal lymphatic system, including its role in immuno-surveillance and immune responses within the meninges and the brain. We will provide a comprehensive update on our current knowledge of meningeal-derived responses across the spectrum of TBI, and identify new avenues for neuroimmune modulation within the neurotrauma field.


Brain Injuries, Traumatic , Meninges , Neuroinflammatory Diseases , Brain Injuries, Traumatic/immunology , Brain Injuries, Traumatic/complications , Brain Injuries, Traumatic/pathology , Humans , Animals , Meninges/immunology , Meninges/pathology , Neuroinflammatory Diseases/immunology , Neuroinflammatory Diseases/etiology , Neuroinflammatory Diseases/pathology , Neuroimmunomodulation/physiology , Neuroimmunomodulation/immunology
2.
Trends Immunol ; 45(5): 325-326, 2024 May.
Article En | MEDLINE | ID: mdl-38637201

To surveil an organ for pathogens, lymphoid structures need to sample antigens locally. The full set of lymphoid structures involved in surveilling for brain-tropic pathogens has not been defined. Through comprehensive imaging of the mouse meninges, a new study by Fitzpatrick et al. describes dural-associated lymphoid tissue (DALT) and its contribution to humoral responses following intranasal viral infection.


Lymphoid Tissue , Animals , Lymphoid Tissue/immunology , Lymphoid Tissue/virology , Humans , Mice , Meninges/immunology , Brain/immunology , Brain/virology , Brain/physiology , Immunity, Humoral
3.
Nature ; 628(8006): 204-211, 2024 Apr.
Article En | MEDLINE | ID: mdl-38418880

The eye, an anatomical extension of the central nervous system (CNS), exhibits many molecular and cellular parallels to the brain. Emerging research demonstrates that changes in the brain are often reflected in the eye, particularly in the retina1. Still, the possibility of an immunological nexus between the posterior eye and the rest of the CNS tissues remains unexplored. Here, studying immune responses to herpes simplex virus in the brain, we observed that intravitreal immunization protects mice against intracranial viral challenge. This protection extended to bacteria and even tumours, allowing therapeutic immune responses against glioblastoma through intravitreal immunization. We further show that the anterior and posterior compartments of the eye have distinct lymphatic drainage systems, with the latter draining to the deep cervical lymph nodes through lymphatic vasculature in the optic nerve sheath. This posterior lymphatic drainage, like that of meningeal lymphatics, could be modulated by the lymphatic stimulator VEGFC. Conversely, we show that inhibition of lymphatic signalling on the optic nerve could overcome a major limitation in gene therapy by diminishing the immune response to adeno-associated virus and ensuring continued efficacy after multiple doses. These results reveal a shared lymphatic circuit able to mount a unified immune response between the posterior eye and the brain, highlighting an understudied immunological feature of the eye and opening up the potential for new therapeutic strategies in ocular and CNS diseases.


Brain , Eye , Lymphatic System , Animals , Female , Humans , Male , Mice , Rabbits , Bacteria/immunology , Brain/anatomy & histology , Brain/immunology , Dependovirus/immunology , Eye/anatomy & histology , Eye/immunology , Glioblastoma/immunology , Herpesvirus 2, Human/immunology , Intravitreal Injections , Lymphatic System/anatomy & histology , Lymphatic System/immunology , Lymphatic Vessels/anatomy & histology , Lymphatic Vessels/immunology , Macaca mulatta , Meninges/immunology , Optic Nerve/immunology , Swine , Zebrafish , Vascular Endothelial Growth Factor C/immunology , Vascular Endothelial Growth Factor C/metabolism , Vascular Endothelial Growth Factor C/pharmacology
4.
Science ; 380(6640): eabo7649, 2023 04 07.
Article En | MEDLINE | ID: mdl-37023203

Contemporary studies have completely changed the view of brain immunity from envisioning the brain as isolated and inaccessible to peripheral immune cells to an organ in close physical and functional communication with the immune system for its maintenance, function, and repair. Circulating immune cells reside in special niches in the brain's borders, the choroid plexus, meninges, and perivascular spaces, from which they patrol and sense the brain in a remote manner. These niches, together with the meningeal lymphatic system and skull microchannels, provide multiple routes of interaction between the brain and the immune system, in addition to the blood vasculature. In this Review, we describe current ideas about brain immunity and their implications for brain aging, diseases, and immune-based therapeutic approaches.


Brain , Immune System , Animals , Humans , Brain/blood supply , Brain/immunology , Cell Movement/immunology , Immune System/cytology , Lymphatic System/immunology , Meninges/immunology , Myeloid Cells/immunology
5.
Nature ; 615(7952): 472-481, 2023 03.
Article En | MEDLINE | ID: mdl-36859544

The meninges are densely innervated by nociceptive sensory neurons that mediate pain and headache1,2. Bacterial meningitis causes life-threatening infections of the meninges and central nervous system, affecting more than 2.5 million people a year3-5. How pain and neuroimmune interactions impact meningeal antibacterial host defences are unclear. Here we show that Nav1.8+ nociceptors signal to immune cells in the meninges through the neuropeptide calcitonin gene-related peptide (CGRP) during infection. This neuroimmune axis inhibits host defences and exacerbates bacterial meningitis. Nociceptor neuron ablation reduced meningeal and brain invasion by two bacterial pathogens: Streptococcus pneumoniae and Streptococcus agalactiae. S. pneumoniae activated nociceptors through its pore-forming toxin pneumolysin to release CGRP from nerve terminals. CGRP acted through receptor activity modifying protein 1 (RAMP1) on meningeal macrophages to polarize their transcriptional responses, suppressing macrophage chemokine expression, neutrophil recruitment and dural antimicrobial defences. Macrophage-specific RAMP1 deficiency or pharmacological blockade of RAMP1 enhanced immune responses and bacterial clearance in the meninges and brain. Therefore, bacteria hijack CGRP-RAMP1 signalling in meningeal macrophages to facilitate brain invasion. Targeting this neuroimmune axis in the meninges can enhance host defences and potentially produce treatments for bacterial meningitis.


Brain , Meninges , Meningitis, Bacterial , Neuroimmunomodulation , Humans , Brain/immunology , Brain/microbiology , Calcitonin Gene-Related Peptide/metabolism , Meninges/immunology , Meninges/microbiology , Meninges/physiopathology , Pain/etiology , NAV1.8 Voltage-Gated Sodium Channel/metabolism , Meningitis, Bacterial/complications , Meningitis, Bacterial/immunology , Meningitis, Bacterial/microbiology , Meningitis, Bacterial/pathology , Streptococcus agalactiae/immunology , Streptococcus agalactiae/pathogenicity , Streptococcus pneumoniae/immunology , Streptococcus pneumoniae/pathogenicity , Nociceptors/metabolism , Receptor Activity-Modifying Protein 1/metabolism , Macrophages/immunology , Macrophages/metabolism
6.
J Exp Med ; 219(3)2022 03 07.
Article En | MEDLINE | ID: mdl-35195681

The gastrointestinal tract contains trillions of microorganisms that exist symbiotically with the host due to a tolerant, regulatory cell-rich intestinal immune system. However, this intimate relationship with the microbiome inevitably comes with risks, with intestinal organisms being the most common cause of bacteremia. The vasculature of the brain-lining meninges contains fenestrated endothelium, conferring vulnerability to invasion by circulating microbes. We propose that this has evolutionarily led to close links between gut and meningeal immunity, to prime the central nervous system defense against the most likely invaders. This paradigm is exemplified by the dural venous sinus IgA defense system, where the antibody repertoire mirrors that of the gut.


Gastrointestinal Tract/immunology , Meninges/immunology , Animals , Gastrointestinal Microbiome/immunology , Humans , Immunoglobulin A/immunology , Meninges/microbiology , Models, Immunological , Plasma Cells/immunology
7.
Article En | MEDLINE | ID: mdl-34911793

BACKGROUND AND OBJECTIVES: To investigate whether the formation or retention of meningeal ectopic lymphoid tissue (mELT) can be inhibited by the sphingosine 1-phosphate receptor 1,5 modulator siponimod (BAF312) in a murine model of multiple sclerosis (MS). METHODS: A murine spontaneous chronic experimental autoimmune encephalomyelitis (EAE) model, featuring meningeal inflammatory infiltrates resembling those in MS, was used. To prevent or treat EAE, siponimod was administered daily starting either before EAE onset or at peak of disease. The extent and cellular composition of mELT, the spinal cord parenchyma, and the spleen was assessed by histology and immunohistochemistry. RESULTS: Siponimod, when applied before disease onset, ameliorated EAE. This effect was also present, although less prominent, when treatment started at peak of disease. Treatment with siponimod resulted in a strong reduction of the extent of mELT in both treatment paradigms. Both B and T cells were diminished in the meningeal compartment. DISCUSSION: Beneficial effects on the disease course correlated with a reduction in mELT, suggesting that inhibition of mELT may be an additional mechanism of action of siponimod in the treatment of EAE. Further studies are needed to establish causality and confirm this observation in MS.


Azetidines/pharmacology , Benzyl Compounds/pharmacology , Encephalomyelitis, Autoimmune, Experimental , Meninges/drug effects , Multiple Sclerosis , Sphingosine 1 Phosphate Receptor Modulators/pharmacology , Tertiary Lymphoid Structures , Animals , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental/complications , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Encephalomyelitis, Autoimmune, Experimental/prevention & control , Humans , Meninges/immunology , Mice , Multiple Sclerosis/complications , Multiple Sclerosis/drug therapy , Multiple Sclerosis/prevention & control , Tertiary Lymphoid Structures/drug therapy , Tertiary Lymphoid Structures/etiology , Tertiary Lymphoid Structures/prevention & control
8.
Cells ; 10(12)2021 12 01.
Article En | MEDLINE | ID: mdl-34943894

The recent (re)discovery of the meningeal lymphatic system has opened new theories as to how immune cells traffic and interact with the central nervous system (CNS). While evidence is accumulating on the contribution of the meningeal lymphatic system in both homeostatic and disease conditions, a lot remains unknown about the mechanisms that allow for interaction between the meningeal lymphatic system and immune cells. In this review, we synthesize the knowledge about the lymphatic immune interaction in the CNS and highlight the important questions that remain to be answered.


Lymphatic Vessels/immunology , Meninges/immunology , Animals , Cell Movement , Homeostasis , Humans , Leukocytes/cytology , Phenotype
9.
Science ; 374(6569): 868-874, 2021 Nov 12.
Article En | MEDLINE | ID: mdl-34648304

Recent studies indicate that the adaptive immune system plays a role in Lewy body dementia (LBD). However, the mechanism regulating T cell brain homing in LBD is unknown. Here, we observed T cells adjacent to Lewy bodies and dopaminergic neurons in postmortem LBD brains. Single-cell RNA sequencing of cerebrospinal fluid (CSF) identified up-regulated expression of C-X-C motif chemokine receptor 4 (CXCR4) in CD4+ T cells in LBD. CSF protein levels of the CXCR4 ligand, C-X-C motif chemokine ligand 12 (CXCL12), were associated with neuroaxonal damage in LBD. Furthermore, we observed clonal expansion and up-regulated interleukin 17A expression by CD4+ T cells stimulated with a phosphorylated α-synuclein epitope. Thus, CXCR4-CXCL12 signaling may represent a mechanistic target for inhibiting pathological interleukin-17­producing T cell trafficking in LBD.


Brain/immunology , Brain/pathology , CD4-Positive T-Lymphocytes/immunology , Lewy Body Disease/immunology , Lewy Body Disease/pathology , Nerve Degeneration , Animals , Brain/blood supply , Brain/metabolism , CD4-Positive T-Lymphocytes/metabolism , Cerebrospinal Fluid/immunology , Chemokine CXCL12/metabolism , Female , Humans , Lewy Body Disease/cerebrospinal fluid , Lewy Body Disease/metabolism , Lymphocyte Activation , Male , Meninges/immunology , Meninges/metabolism , Mice , Mice, Inbred C57BL , Receptors, CXCR4/genetics , Receptors, CXCR4/metabolism , Signal Transduction , T-Lymphocyte Subsets/immunology , Th17 Cells/immunology , Up-Regulation , alpha-Synuclein/analysis
10.
Immunity ; 54(12): 2784-2794.e6, 2021 12 14.
Article En | MEDLINE | ID: mdl-34626548

Self-reactive B cell progenitors are eliminated through central tolerance checkpoints, a process thought to be restricted to the bone marrow in mammals. Here, we identified a consecutive trajectory of B cell development in the meninges of mice and non-human primates. The meningeal B cells were located predominantly at the dural sinuses, where endothelial cells expressed essential niche factors to support B cell development. Parabiosis experiments together with lineage tracing showed that meningeal developing B cells were replenished continuously from hematopoietic stem cell (HSC)-derived progenitors via a circulation-independent route. Autoreactive immature B cells that recognized myelin oligodendrocyte glycoprotein (MOG), a central nervous system-specific antigen, were eliminated specifically from the meninges. Furthermore, genetic deletion of the Mog gene restored the self-reactive B cell population in the meninges. These findings identify the meninges as a distinct reservoir for B cell development, allowing in situ negative selection to ensure a locally non-self-reactive immune repertoire.


Dendritic Cells/immunology , Hematopoietic Stem Cells/physiology , Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism , Meninges/immunology , Plasma Cells/immunology , Animals , Antibodies, Neutralizing/metabolism , B7-1 Antigen/metabolism , CD28 Antigens/metabolism , Cell Self Renewal , Cell Survival , Cells, Cultured , Humans , Immunity, Humoral , Immunologic Memory , Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics , Mice , Mice, Inbred C57BL
11.
Exp Mol Med ; 53(9): 1251-1267, 2021 09.
Article En | MEDLINE | ID: mdl-34489558

Recent research into meningeal lymphatics has revealed a never-before appreciated role of type II innate lymphoid cells (ILC2s) in modulating neuroinflammation in the central nervous system (CNS). To date, the role of ILC2-mediated inflammation in the periphery has been well studied. However, the exact distribution of ILC2s in the CNS and therefore their putative role in modulating neuroinflammation in neurodegenerative diseases such as Alzheimer's disease (AD), multiple sclerosis (MS), Parkinson's disease (PD), and major depressive disorder (MDD) remain highly elusive. Here, we review the current evidence of ILC2-mediated modulation of neuroinflammatory cues (i.e., IL-33, IL-25, IL-5, IL-13, IL-10, TNFα, and CXCL16-CXCR6) within the CNS, highlight the distribution of ILC2s in both the periphery and CNS, and discuss some challenges associated with cell type-specific targeting that are important for therapeutics. A comprehensive understanding of the roles of ILC2s in mediating and responding to inflammatory cues may provide valuable insight into potential therapeutic strategies for many dementia-related disorders.


Immunity, Innate , Lymphocyte Subsets/immunology , Lymphocyte Subsets/metabolism , Meninges/metabolism , Neurodegenerative Diseases/etiology , Neurodegenerative Diseases/metabolism , Neuroinflammatory Diseases/complications , Animals , Biomarkers , Brain/metabolism , Cytokines/metabolism , Diagnosis, Differential , Disease Susceptibility , Humans , Immunomodulation , Lymphatic System/immunology , Lymphatic System/metabolism , Meninges/immunology , Neurodegenerative Diseases/diagnosis , Neuroimmunomodulation , Neuroinflammatory Diseases/etiology , Neuroinflammatory Diseases/metabolism
12.
Proc Natl Acad Sci U S A ; 118(36)2021 09 07.
Article En | MEDLINE | ID: mdl-34479995

Ectopic lymphoid tissue containing B cells forms in the meninges at late stages of human multiple sclerosis (MS) and when neuroinflammation is induced by interleukin (IL)-17 producing T helper (Th17) cells in rodents. B cell differentiation and the subsequent release of class-switched immunoglobulins have been speculated to occur in the meninges, but the exact cellular composition and underlying mechanisms of meningeal-dominated inflammation remain unknown. Here, we performed in-depth characterization of meningeal versus parenchymal Th17-induced rodent neuroinflammation. The most pronounced cellular and transcriptional differences between these compartments was the localization of B cells exhibiting a follicular phenotype exclusively to the meninges. Correspondingly, meningeal but not parenchymal Th17 cells acquired a B cell-supporting phenotype and resided in close contact with B cells. This preferential B cell tropism for the meninges and the formation of meningeal ectopic lymphoid tissue was partially dependent on the expression of the transcription factor Bcl6 in Th17 cells that is required in other T cell lineages to induce isotype class switching in B cells. A function of Bcl6 in Th17 cells was only detected in vivo and was reflected by the induction of B cell-supporting cytokines, the appearance of follicular B cells in the meninges, and of immunoglobulin class switching in the cerebrospinal fluid. We thus identify the induction of a B cell-supporting meningeal microenvironment by Bcl6 in Th17 cells as a mechanism controlling compartment specificity in neuroinflammation.


Neuroinflammatory Diseases/metabolism , Proto-Oncogene Proteins c-bcl-6/metabolism , Th17 Cells/metabolism , Animals , B-Lymphocytes/immunology , Cell Communication , Cytokines/metabolism , Encephalomyelitis, Autoimmune, Experimental/metabolism , Female , Germinal Center/immunology , Inflammation/metabolism , Lymphocyte Activation , Male , Meninges/immunology , Meninges/metabolism , Mice , Mice, Inbred C57BL , Multiple Sclerosis/metabolism , Neuroinflammatory Diseases/immunology , Neuroinflammatory Diseases/physiopathology , Parenchymal Tissue/immunology , Parenchymal Tissue/metabolism , Proto-Oncogene Proteins c-bcl-6/physiology , Th17 Cells/immunology , Th17 Cells/physiology
13.
Cells ; 10(7)2021 07 06.
Article En | MEDLINE | ID: mdl-34359880

An imbalance of TNF signalling in the inflammatory milieu generated by meningeal immune cell infiltrates in the subarachnoid space in multiple sclerosis (MS), and its animal model may lead to increased cortical pathology. In order to explore whether this feature may be present from the early stages of MS and may be associated with the clinical outcome, the protein levels of TNF, sTNF-R1 and sTNF-R2 were assayed in CSF collected from 122 treatment-naïve MS patients and 36 subjects with other neurological conditions at diagnosis. Potential correlations with other CSF cytokines/chemokines and with clinical and imaging parameters at diagnosis (T0) and after 2 years of follow-up (T24) were evaluated. Significantly increased levels of TNF (fold change: 7.739; p < 0.001), sTNF-R1 (fold change: 1.693; p < 0.001) and sTNF-R2 (fold change: 2.189; p < 0.001) were detected in CSF of MS patients compared to the control group at T0. Increased TNF levels in CSF were significantly (p < 0.01) associated with increased EDSS change (r = 0.43), relapses (r = 0.48) and the appearance of white matter lesions (r = 0.49). CSF levels of TNFR1 were associated with cortical lesion volume (r = 0.41) at T0, as well as with new cortical lesions (r = 0.56), whilst no correlation could be found between TNFR2 levels in CSF and clinical or MRI features. Combined correlation and pathway analysis (ingenuity) of the CSF protein pattern associated with TNF expression (encompassing elevated levels of BAFF, IFN-γ, IL-1ß, IL-10, IL-8, IL-16, CCL21, haptoglobin and fibrinogen) showed a particular relationship to the interaction between innate and adaptive immune response. The CSF sTNF-R1-associated pattern (encompassing high levels of CXCL13, TWEAK, LIGHT, IL-35, osteopontin, pentraxin-3, sCD163 and chitinase-3-L1) was mainly related to altered T cell and B cell signalling. Finally, the CSF TNFR2-associated pattern (encompassing high CSF levels of IFN-ß, IFN-λ2, sIL-6Rα) was linked to Th cell differentiation and regulatory cytokine signalling. In conclusion, dysregulation of TNF and TNF-R1/2 pathways associates with specific clinical/MRI profiles and can be identified at a very early stage in MS patients, at the time of diagnosis, contributing to the prediction of the disease outcome.


Multiple Sclerosis/diagnostic imaging , Multiple Sclerosis/genetics , Receptors, Tumor Necrosis Factor, Type II/genetics , Receptors, Tumor Necrosis Factor, Type I/genetics , Tumor Necrosis Factor-alpha/genetics , Adaptive Immunity , Adult , Antigens, CD/cerebrospinal fluid , Antigens, CD/genetics , Antigens, CD/immunology , Antigens, Differentiation, Myelomonocytic/cerebrospinal fluid , Antigens, Differentiation, Myelomonocytic/genetics , Antigens, Differentiation, Myelomonocytic/immunology , B-Lymphocytes/immunology , B-Lymphocytes/pathology , C-Reactive Protein/cerebrospinal fluid , C-Reactive Protein/genetics , C-Reactive Protein/immunology , Case-Control Studies , Cerebral Cortex/diagnostic imaging , Cerebral Cortex/immunology , Cerebral Cortex/pathology , Chemokine CXCL13/cerebrospinal fluid , Chemokine CXCL13/genetics , Chemokine CXCL13/immunology , Chitinase-3-Like Protein 1/cerebrospinal fluid , Chitinase-3-Like Protein 1/genetics , Chitinase-3-Like Protein 1/immunology , Cytokine TWEAK/cerebrospinal fluid , Cytokine TWEAK/genetics , Cytokine TWEAK/immunology , Early Diagnosis , Female , Gene Expression Regulation , Humans , Immunity, Innate , Interleukins/cerebrospinal fluid , Interleukins/genetics , Interleukins/immunology , Magnetic Resonance Imaging , Male , Meninges/diagnostic imaging , Meninges/immunology , Meninges/pathology , Multiple Sclerosis/cerebrospinal fluid , Multiple Sclerosis/pathology , Osteopontin/cerebrospinal fluid , Osteopontin/genetics , Osteopontin/immunology , Receptors, Cell Surface/genetics , Receptors, Cell Surface/immunology , Receptors, Tumor Necrosis Factor, Type I/cerebrospinal fluid , Receptors, Tumor Necrosis Factor, Type I/immunology , Receptors, Tumor Necrosis Factor, Type II/cerebrospinal fluid , Receptors, Tumor Necrosis Factor, Type II/immunology
14.
Nat Neurosci ; 24(9): 1225-1234, 2021 09.
Article En | MEDLINE | ID: mdl-34253922

The CNS is ensheathed by the meninges and cerebrospinal fluid, and recent findings suggest that these CNS-associated border tissues have complex immunological functions. Unlike myeloid lineage cells, lymphocytes in border compartments have yet to be thoroughly characterized. Based on single-cell transcriptomics, we here identified a highly location-specific composition and expression profile of tissue-resident leukocytes in CNS parenchyma, pia-enriched subdural meninges, dura mater, choroid plexus and cerebrospinal fluid. The dura layer of the meninges contained a large population of B cells under homeostatic conditions in mice and rats. Murine dura B cells exhibited slow turnover and long-term tissue residency, and they matured in experimental neuroinflammation. The dura also contained B lineage progenitors at the pro-B cell stage typically not found outside of bone marrow, without direct influx from the periphery or the skull bone marrow. This identified the dura as an unexpected site of B cell residence and potentially of development in both homeostasis and neuroinflammation.


B-Lymphocytes/immunology , Meninges/immunology , Precursor Cells, B-Lymphoid/immunology , Animals , Mice , Rats , Single-Cell Analysis
15.
Immunology ; 164(3): 450-466, 2021 11.
Article En | MEDLINE | ID: mdl-34293193

Ectopic lymphoid follicles (ELFs), resembling germinal centre-like structures, emerge in a variety of infectious and autoimmune and neoplastic diseases. ELFs can be found in the meninges of around 40% of the investigated progressive multiple sclerosis (MS) post-mortem brain tissues and are associated with the severity of cortical degeneration and clinical disease progression. Of predominant importance for progressive neuronal damage during the progressive MS phase appears to be meningeal inflammation, comprising diffuse meningeal infiltrates, B-cell aggregates and compartmentalized ELFs. However, the absence of a uniform definition of ELFs impedes reproducible and comparable neuropathological research in this field. In this review article, we will first highlight historical aspects and milestones around the discovery of ELFs in the meninges of progressive MS patients. In the next step, we discuss how animal models may contribute to an understanding of the mechanisms underlying ELF formation. Finally, we summarize challenges in investigating ELFs and propose potential directions for future research.


Meninges/pathology , Multiple Sclerosis, Chronic Progressive/immunology , Tertiary Lymphoid Structures/immunology , Animals , B-Lymphocytes/immunology , Disease Models, Animal , Humans , Meninges/immunology , Multiple Sclerosis, Chronic Progressive/pathology , Tertiary Lymphoid Structures/pathology
16.
Front Immunol ; 12: 688254, 2021.
Article En | MEDLINE | ID: mdl-34093593

Several barriers separate the central nervous system (CNS) from the rest of the body. These barriers are essential for regulating the movement of fluid, ions, molecules, and immune cells into and out of the brain parenchyma. Each CNS barrier is unique and highly dynamic. Endothelial cells, epithelial cells, pericytes, astrocytes, and other cellular constituents each have intricate functions that are essential to sustain the brain's health. Along with damaging neurons, a traumatic brain injury (TBI) also directly insults the CNS barrier-forming cells. Disruption to the barriers first occurs by physical damage to the cells, called the primary injury. Subsequently, during the secondary injury cascade, a further array of molecular and biochemical changes occurs at the barriers. These changes are focused on rebuilding and remodeling, as well as movement of immune cells and waste into and out of the brain. Secondary injury cascades further damage the CNS barriers. Inflammation is central to healthy remodeling of CNS barriers. However, inflammation, as a secondary pathology, also plays a role in the chronic disruption of the barriers' functions after TBI. The goal of this paper is to review the different barriers of the brain, including (1) the blood-brain barrier, (2) the blood-cerebrospinal fluid barrier, (3) the meningeal barrier, (4) the blood-retina barrier, and (5) the brain-lesion border. We then detail the changes at these barriers due to both primary and secondary injury following TBI and indicate areas open for future research and discoveries. Finally, we describe the unique function of the pro-inflammatory cytokine interleukin-1 as a central actor in the inflammatory regulation of CNS barrier function and dysfunction after a TBI.


Blood-Brain Barrier/metabolism , Blood-Retinal Barrier/metabolism , Brain Injuries, Traumatic/metabolism , Inflammation Mediators/metabolism , Inflammation/metabolism , Interleukin-1/metabolism , Meninges/metabolism , Animals , Anti-Inflammatory Agents/pharmacology , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/immunology , Blood-Brain Barrier/pathology , Blood-Retinal Barrier/drug effects , Blood-Retinal Barrier/immunology , Blood-Retinal Barrier/pathology , Brain Injuries, Traumatic/drug therapy , Brain Injuries, Traumatic/immunology , Brain Injuries, Traumatic/pathology , Humans , Inflammation/drug therapy , Inflammation/immunology , Inflammation/pathology , Inflammation Mediators/antagonists & inhibitors , Interleukin-1/antagonists & inhibitors , Meninges/drug effects , Meninges/immunology , Meninges/pathology , Receptors, Interleukin-1 Type I/metabolism , Signal Transduction
17.
J Immunol ; 207(1): 44-54, 2021 07 01.
Article En | MEDLINE | ID: mdl-34162727

Multiple sclerosis (MS) is an idiopathic demyelinating disease in which meningeal inflammation correlates with accelerated disease progression. The study of meningeal inflammation in MS has been limited because of constrained access to MS brain/spinal cord specimens and the lack of experimental models recapitulating progressive MS. Unlike induced models, a spontaneously occurring model would offer a unique opportunity to understand MS immunopathogenesis and provide a compelling framework for translational research. We propose granulomatous meningoencephalomyelitis (GME) as a natural model to study neuropathological aspects of MS. GME is an idiopathic, progressive neuroinflammatory disease of young dogs with a female bias. In the GME cases examined in this study, the meninges displayed focal and disseminated leptomeningeal enhancement on magnetic resonance imaging, which correlated with heavy leptomeningeal lymphocytic infiltration. These leptomeningeal infiltrates resembled tertiary lymphoid organs containing large B cell clusters that included few proliferating Ki67+ cells, plasma cells, follicular dendritic/reticular cells, and germinal center B cell-like cells. These B cell collections were confined in a specialized network of collagen fibers associated with the expression of the lympho-organogenic chemokines CXCL13 and CCL21. Although neuroparenchymal perivascular infiltrates contained B cells, they lacked the immune signature of aggregates in the meningeal compartment. Finally, meningeal B cell accumulation correlated significantly with cortical demyelination reflecting neuropathological similarities to MS. Hence, during chronic neuroinflammation, the meningeal microenvironment sustains B cell accumulation that is accompanied by underlying neuroparenchymal injury, indicating GME as a novel, naturally occurring model to study compartmentalized neuroinflammation and the associated pathology thought to contribute to progressive MS.


B-Lymphocytes/immunology , Disease Models, Animal , Meninges/immunology , Multiple Sclerosis, Chronic Progressive/immunology , Animals , B-Lymphocytes/pathology , Dogs , Meninges/pathology , Multiple Sclerosis, Chronic Progressive/pathology
18.
Science ; 373(6553)2021 07 23.
Article En | MEDLINE | ID: mdl-34083447

The meninges are a membranous structure enveloping the central nervous system (CNS) that host a rich repertoire of immune cells mediating CNS immune surveillance. Here, we report that the mouse meninges contain a pool of monocytes and neutrophils supplied not from the blood but by adjacent skull and vertebral bone marrow. Under pathological conditions, including spinal cord injury and neuroinflammation, CNS-infiltrating myeloid cells can originate from brain borders and display transcriptional signatures distinct from their blood-derived counterparts. Thus, CNS borders are populated by myeloid cells from adjacent bone marrow niches, strategically placed to supply innate immune cells under homeostatic and pathological conditions. These findings call for a reinterpretation of immune-cell infiltration into the CNS during injury and autoimmunity and may inform future therapeutic approaches that harness meningeal immune cells.


Bone Marrow Cells/physiology , Central Nervous System Diseases/immunology , Central Nervous System/immunology , Meninges/immunology , Myeloid Cells/physiology , Skull/anatomy & histology , Spine/anatomy & histology , Animals , Bone Marrow/physiology , Brain/cytology , Brain/immunology , Brain/physiology , Cell Movement , Central Nervous System/cytology , Central Nervous System Diseases/pathology , Dura Mater/cytology , Dura Mater/immunology , Dura Mater/physiology , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/pathology , Homeostasis , Meninges/cytology , Meninges/physiology , Mice , Monocytes/physiology , Neutrophils/physiology , Spinal Cord/cytology , Spinal Cord/immunology , Spinal Cord/physiology , Spinal Cord Injuries/immunology , Spinal Cord Injuries/pathology
19.
Science ; 373(6553)2021 07 23.
Article En | MEDLINE | ID: mdl-34083450

The meninges contain adaptive immune cells that provide immunosurveillance of the central nervous system (CNS). These cells are thought to derive from the systemic circulation. Through single-cell analyses, confocal imaging, bone marrow chimeras, and parabiosis experiments, we show that meningeal B cells derive locally from the calvaria, which harbors a bone marrow niche for hematopoiesis. B cells reach the meninges from the calvaria through specialized vascular connections. This calvarial-meningeal path of B cell development may provide the CNS with a constant supply of B cells educated by CNS antigens. Conversely, we show that a subset of antigen-experienced B cells that populate the meninges in aging mice are blood-borne. These results identify a private source for meningeal B cells, which may help maintain immune privilege within the CNS.


B-Lymphocyte Subsets/physiology , B-Lymphocytes/physiology , Bone Marrow Cells/physiology , Central Nervous System/immunology , Dura Mater/cytology , Lymphopoiesis , Meninges/cytology , Meninges/immunology , Skull/anatomy & histology , Aging , Animals , B-Lymphocyte Subsets/immunology , Cell Movement , Central Nervous System/physiology , Dura Mater/immunology , Fibroblasts/physiology , Homeostasis , Immune Privilege , Mice , Plasma Cells/physiology , Single-Cell Analysis
20.
Article En | MEDLINE | ID: mdl-34021057

OBJECTIVE: To investigate whether anti-CD20 B-cell-depleting monoclonal antibodies (ɑCD20 mAbs) inhibit the formation or retention of meningeal ectopic lymphoid tissue (mELT) in a murine model of multiple sclerosis (MS). METHODS: We used a spontaneous chronic experimental autoimmune encephalomyelitis (EAE) model of mice with mutant T-cell and B-cell receptors specific for myelin oligodendrocyte glycoprotein (MOG), which develop meningeal inflammatory infiltrates resembling those described in MS. ɑCD20 mAbs were administered in either a preventive or a treatment regimen. The extent and cellular composition of mELT was assessed by histology and immunohistochemistry. RESULTS: ɑCD20 mAb, applied in a paradigm to either prevent or treat EAE, did not alter the disease course in either condition. However, ɑCD20 mAb depleted virtually all B cells from the meningeal compartment but failed to prevent the formation of mELT altogether. Because of the absence of B cells, mELT was less densely populated with immune cells and the cellular composition was changed, with increased neutrophil granulocytes. CONCLUSIONS: These results demonstrate that, in CNS autoimmune disease, meningeal inflammatory infiltrates may form and persist in the absence of B cells. Together with the finding that ɑCD20 mAb does not ameliorate spontaneous chronic EAE with mELT, our data suggest that mELT may have yet unknown capacities that are independent of B cells and contribute to CNS autoimmunity.


Antibodies, Monoclonal/pharmacology , Antigens, CD20/immunology , B-Lymphocytes , Encephalomyelitis, Autoimmune, Experimental , Immunologic Factors/pharmacology , Meninges , Tertiary Lymphoid Structures , Animals , Antibodies, Monoclonal/administration & dosage , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/prevention & control , Immunologic Factors/administration & dosage , Meninges/drug effects , Meninges/immunology , Mice , Mice, Transgenic , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Multiple Sclerosis/prevention & control , Myelin-Oligodendrocyte Glycoprotein , Tertiary Lymphoid Structures/drug therapy , Tertiary Lymphoid Structures/immunology
...